A quantitative analytical investigation on the oxycodone side effects listed in recent clinical trials

• Authors: Alireza Ghassemi Toussi , Farshad Ghassemi Toosi

Abstracts

EN

Background: Oxycodone is a semi-synthetic narcotic analgesic medication with numerous side eefcts. Patients who use oxycodone may have one or more side eefcts depending on their clinical status and/or other factors. Our aim was to analyze clinical trials for any potential paetrn related to the side eefcts of oxycodone. Methods: We searched the ClinicalTrials.gov database for clinical studies conducted around the world regarding oxycodone. A number of general data analytic and text manipulation techniques were used in the Python programming language. Results: We analyzed 842 clinical trials involving oxycodone. Our results suggest that the researchers focused on oxycodone's typical side eefcts (e.g. vomiting), as opposed to the less evident and/or long-term side eefcts e.g. depression, confusion and constipation. Conclusions: The adverse eefcts of oxycodone most commonly reported in the clinical trials are nausea, vomiting and depression. Despite the clinical use of oxycodone in all the age groups (including infants), very few of the publicly-available clinical trials included participants < 18 years of age. Toussi AG, Toosi FG. A quantitative analytical investigation on the oxycodone side eefcts listed in recent clinical trials. Eur J Transl Clin Med. 2023;6(1):58-63.

Keywords

EN

oxycodone; nausea; vomiting; itching; confusion

• Publisher: Gdański Uniwersytet Medyczny
• Journal: European Journal of Translational and Clinical Medicine
• Year: 2023
• Volume: 6
• Issue: 1
• Pages: 58-63

Dates

published

2023

Contributors

author

Alireza Ghassemi Toussi

• Mashhad University of Medical Science, Mashhad, Iran

author

Farshad Ghassemi Toosi

• Munster Technological University, Cork, Ireland

References

• 1. Alcohol and Drug Policy Commission: Opiates or Opioids - What's the diefrence?: State of Oregon [Internet]. oregon.gov. [cited 2023 May 4]. Available from: htps://www.oregon.gov/adpc/pages/opiate-opioid.aspx
• 2. Schmidt-Hansen M, Bennet MI, Arnold S, Bromham N, Hilgart JS, Page AJ, et al. Oxycodone for cancer -related pain. Cochrane Database Syst Rev [Internet]. 2022;(6). Available from: htps://doi.org//10.1002/14651858.CD003870.pub7
• 3. Leppert W. Role of oxycodone and oxycodone/naloxone in cancer pain management. Pharmacol Reports [Internet]. 2010;62(4):578-91. Available from: htps://www.sciencedirect.com/science/article/pii/S1734114010703169
• 4. Quirion B, Bergeron F, Blais V, Gendron L. The Delta-Opioid Receptor; a Target for the Treatment of Pain. Front Mol Neurosci [Internet]. 2020;13. Available from: htps://www.frontiersin.org/article/10.3389/fnmol.2020.00052/full
• 5. Kenan K, Mack K, Paulozzi L. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000-2010. Open Med [Internet]. 2012;6(2):e41. Available from: htps://www.scienceopen.com/document_file/ 5da741e6-b2ee-4fda-af17-210a65519091/PubMedCentral/5da741e6-b2ee-4fda-af17-210a65519091.pdf
• 6. Morse JD, Hannam JA, Anderson BJ, Kokki H, Kokki M. Oxycodone target concentration dosing for acute pain in children. Pediatr Anesth [Internet]. 2021;31(12):1325-31. Available from: htps://doi.org/10.1111/pan.14282
• 7. Ordóñez Gallego A, González Barón M, Espinosa Arranz E. Oxycodone: a pharmacological and clinical review. Clin Transl Oncol [Internet]. 2007;9(5):298-307. Available from: htps://doi.org/10.1007/s12094-007-0057-9
• 8. Burness CB, Keating GM. Oxycodone/Naloxone Prolonged-Release: A Review of Its Use in the Management of Chronic Pain While Counteracting Opioid-Induced Constipation. Drugs [Internet]. 2014;74(3):353-75. Available from: htps://doi. org/10.1007/s40265-014-0177-9
• 9. Andreassen TN, Klepstad P, Davies A, Bjordal K, Lundström S, Kaasa S, et al. Is Oxycodone Eficacy Reflected in Serum Concentrations? A Multicenter, Cross-Sectional Study in 456 Adult Cancer Patients. J Pain Symptom Manage [Internet]. 2012;43(4):694-705. Available from: htps://www.sciencedirect.com/science/article/pii/S0885392411005148
• 10. Czarnecki ML, Jandrisevits MD, Theiler SC, Huth MM, Weisman SJ. Controlled-release oxycodone for the management of pediatric postoperative pain. J Pain Symptom Manage [Internet]. 2004;27(4):379-86. Available from: htps://www.sci - encedirect.com/science/article/pii/S0885392404000028
• 11. Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept [Internet]. 2009;155(1):11-7. Available from: htps:// www.sciencedirect.com/science/article/pii/S0167011509000731
• 12. Kanemasa T, Koike K, Takase K, Arai T, Nakamura A, Morioka Y, et al. Pharmacological Profile of Naldemedine, a Peripherally Acting μ-Opioid Receptor Antagonist: Comparison with Naloxone and Naloxegol. J Pharmacol Exp Ther [Internet]. 2020;373(3):438 LP - 444. Available from: htp://jpet.aspetjournals.org/content/373/3/438.abstract
• 13. Wilens TE, Hammerness PG, Biederman J. The Changing Face of Teenage Drug Abuse -The Trend toward Prescription Drugs. Psychiatry [Internet]. 2005;66:253-9. Available from: htp://www.lynneshealth.com/resources/Kids/Teenage drug abuse.pdf
• 14. Jones JD, Vosburg SK, Manubay JM, Comer SD. Oxycodone Abuse in New York City: Characteristics of Intravenous and Intranasal Users. Am J Addict [Internet]. 2011;20(3):190-5. Available from: htps://doi.org/10.1111/j.1521-0391.2011.00120.x
• 15. Kemppainen V, Mentula M, Palkama V, Heikinheimo O. Pain during medical aborotin in early pregnancy in teenage and adult women. Acta Obstet Gynecol Scand [Internet]. 2020;99(12):1603-10. Available from: hpts://doi.org/10.1111/aogs.13920

Identifiers

DOI

10.31373/ejtcm/163415

Biblioteka Nauki

2203242